Overview

Study to Evaluate the Safety and Efficacy of Two Adalimumab Dosing Regimens in Subjects With Moderate to Severe Ulcerative Colitis

Status:
Completed

Trial end date:
2019-11-11

Target enrollment:

Participant gender:

Summary

To evaluate safety and efficacy of two adalimumab dosing regimens for induction and maintenance (standard and higher dosing) in achieving clinical remission in subjects with moderately to severely active ulcerative colitis.

Phase:

Phase 3

Details

Lead Sponsor:

AbbVie

Treatments:

Adalimumab